IBDEI2KY ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,43278,1,4,0)
 ;;=4^Z01.419
 ;;^UTILITY(U,$J,358.3,43278,2)
 ;;=^5062623
 ;;^UTILITY(U,$J,358.3,43279,0)
 ;;=Z01.411^^197^2184^7
 ;;^UTILITY(U,$J,358.3,43279,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43279,1,3,0)
 ;;=3^Gyn Exam w/ Abnormal Findings
 ;;^UTILITY(U,$J,358.3,43279,1,4,0)
 ;;=4^Z01.411
 ;;^UTILITY(U,$J,358.3,43279,2)
 ;;=^5062622
 ;;^UTILITY(U,$J,358.3,43280,0)
 ;;=Z00.01^^197^2184^5
 ;;^UTILITY(U,$J,358.3,43280,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43280,1,3,0)
 ;;=3^General Medical Exam w/ Abnormal Findings
 ;;^UTILITY(U,$J,358.3,43280,1,4,0)
 ;;=4^Z00.01
 ;;^UTILITY(U,$J,358.3,43280,2)
 ;;=^5062600
 ;;^UTILITY(U,$J,358.3,43281,0)
 ;;=Z02.0^^197^2184^2
 ;;^UTILITY(U,$J,358.3,43281,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43281,1,3,0)
 ;;=3^Exam for Admission to Educational Institution
 ;;^UTILITY(U,$J,358.3,43281,1,4,0)
 ;;=4^Z02.0
 ;;^UTILITY(U,$J,358.3,43281,2)
 ;;=^5062633
 ;;^UTILITY(U,$J,358.3,43282,0)
 ;;=Z02.2^^197^2184^3
 ;;^UTILITY(U,$J,358.3,43282,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43282,1,3,0)
 ;;=3^Exam for Admission to Residential Institution
 ;;^UTILITY(U,$J,358.3,43282,1,4,0)
 ;;=4^Z02.2
 ;;^UTILITY(U,$J,358.3,43282,2)
 ;;=^5062635
 ;;^UTILITY(U,$J,358.3,43283,0)
 ;;=Z85.43^^197^2185^51
 ;;^UTILITY(U,$J,358.3,43283,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43283,1,3,0)
 ;;=3^Personal Hx of Malig Neop Ovary
 ;;^UTILITY(U,$J,358.3,43283,1,4,0)
 ;;=4^Z85.43
 ;;^UTILITY(U,$J,358.3,43283,2)
 ;;=^5063420
 ;;^UTILITY(U,$J,358.3,43284,0)
 ;;=Z85.46^^197^2185^52
 ;;^UTILITY(U,$J,358.3,43284,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43284,1,3,0)
 ;;=3^Personal Hx of Malig Neop Prostate
 ;;^UTILITY(U,$J,358.3,43284,1,4,0)
 ;;=4^Z85.46
 ;;^UTILITY(U,$J,358.3,43284,2)
 ;;=^5063423
 ;;^UTILITY(U,$J,358.3,43285,0)
 ;;=Z85.6^^197^2185^49
 ;;^UTILITY(U,$J,358.3,43285,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43285,1,3,0)
 ;;=3^Personal Hx of Leukemia
 ;;^UTILITY(U,$J,358.3,43285,1,4,0)
 ;;=4^Z85.6
 ;;^UTILITY(U,$J,358.3,43285,2)
 ;;=^5063434
 ;;^UTILITY(U,$J,358.3,43286,0)
 ;;=Z85.71^^197^2185^47
 ;;^UTILITY(U,$J,358.3,43286,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43286,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,43286,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,43286,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,43287,0)
 ;;=Z85.820^^197^2185^50
 ;;^UTILITY(U,$J,358.3,43287,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43287,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of SKin
 ;;^UTILITY(U,$J,358.3,43287,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,43287,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,43288,0)
 ;;=Z85.828^^197^2185^53
 ;;^UTILITY(U,$J,358.3,43288,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43288,1,3,0)
 ;;=3^Personal Hx of Malig Neop Skin
 ;;^UTILITY(U,$J,358.3,43288,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,43288,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,43289,0)
 ;;=Z65.8^^197^2185^58
 ;;^UTILITY(U,$J,358.3,43289,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43289,1,3,0)
 ;;=3^Personal Hx of Psychosocial Circumstance Problems
 ;;^UTILITY(U,$J,358.3,43289,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,43289,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,43290,0)
 ;;=Z86.718^^197^2185^61
 ;;^UTILITY(U,$J,358.3,43290,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,43290,1,3,0)
 ;;=3^Personal Hx of Venous Thrombosis & Embolism
 ;;^UTILITY(U,$J,358.3,43290,1,4,0)
 ;;=4^Z86.718
 ;;^UTILITY(U,$J,358.3,43290,2)
 ;;=^5063475
 ;;^UTILITY(U,$J,358.3,43291,0)
 ;;=Z86.73^^197^2185^60
 ;;^UTILITY(U,$J,358.3,43291,1,0)
 ;;=^358.31IA^4^2
